10
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Salvage high-dose rate brachytherapy for myxofibrosarcoma of the brachium: a technical report

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          An 80-year-old male presented with T1N0M0 myxofibrosarcoma in or next to the humeral canal, which is located between the biceps and triceps of the right upper arm. Because the tumor was close to critical anatomical structures such as the brachial artery, median nerve and ulnar nerve, it was deemed impossible to perform limb-sparing surgery with an adequate resection margin. Therefore, preoperative external beam radiation therapy (EBRT) followed by limb-sparing surgery was offered. Magnetic resonance imaging taken after 40 Gy/20 fractions of EBRT showed an inadequate response, and limb-sparing surgery was not deemed possible at this point. Amputation of the right arm was offered, but the patient refused. Therefore, salvage high-dose-rate interstitial brachytherapy (HDR-ISBT) was offered. Under local anesthesia and sedation, 14 plastic needles were inserted, and 36 Gy in 6 fractions of HDR-ISBT was performed. Although radiation-induced incomplete paralysis of the median nerve was noted, no local progression or distant metastasis was found on the CT that was taken 2 years after the treatment.

          Related collections

          Most cited references11

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Guidelines for the Management of Soft Tissue Sarcomas

          These guidelines were drawn up following a consensus meeting of UK sarcoma specialists convened under the auspices of the British Sarcoma Group and are intended to provide a framework for the multidisciplinary care of patients with soft tissue sarcomas. The guidelines published by the European Society of Medical Oncology (ESMO) and the National Comprehensive Cancer Network (NCCN) were used as the basis for discussion and adapted according to UK clinical practice and local requirements. Note was also taken of the National Institute for Health and Clinical Excellence (NICE) improving outcomes guidance (IOG) for people with sarcoma and existing technology appraisals. The guidelines are not intended to challenge NICE guidance but discrepancies may exist where current guidance does not reflect an international standard of care owing to the ever-evolving nature of cancer treatment. It is acknowledged that these guidelines will require updating on a regular basis. An appendix lists the key recommendations which are summarised below. Any patient with a suspected soft tissue sarcoma should be referred to a diagnostic centre and managed by a specialist sarcoma multidisciplinary team. Surgical excision followed by post operative radiotherapy is the standard management of high grade limb sarcomas although occasionally amputation remains the only option. Pre-operative treatment with chemotherapy or radiotherapy should be considered for patients with borderline resectable tumours. Isolated limb perfusion may permit limb salvage in some cases where amputation is the only other option. Adjuvant chemotherapy is not routinely recommended but may be considered in certain specific situations. Regular follow up is recommended to assess local control and the development of metastatic disease. Single agent doxorubicin is the standard first line therapy for metastatic disease. Ifosfamide is an alternative if anthracyclines are contraindicated. Combination therapy may be considered in individual patients. Second line agents include ifosfamide, dacarbazine, trabectedin and the combination of gemcitabine + docetaxel. Surgical resection of local recurrence and pulmonary metastases should be considered in individual patients. There is specific guidance on the management of retroperitoneal and uterine sarcomas.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Prognostic factors and outcomes of patients with myxofibrosarcoma.

            Myxofibrosarcomas (MFS) are a historically heterogeneous group of tumors that exhibit a propensity for local recurrence. The objectives of this study were to analyze the prognostic factors and outcomes of patients with MFS treated at a single institution. We retrospectively reviewed the records of 69 consecutive patients with pathologically confirmed MFS of the extremities or superficial trunk who underwent surgery from August 1995 to November 2010. Clinicopathologic features, treatments, and patient outcomes were reviewed. Sixty-nine patients were identified, of whom 38 were men (55%). The median age was 62 years. Sixty-four patients (93%) presented with primary tumors, and 5 patients (7%) presented with locally recurrent tumors. Median tumor size was 6.0 cm, and 44 patients (64%) had grade 3 tumors (FNCLCC [Fédération Nationale des Centres de Lutte Contre le Cancer] classification). Margins were microscopically positive in 14 patients (20%) and negative in 55 patients (80%), including close margins (<1 mm) in 14 patients (20%). Fifty-three patients (77%) received radiotherapy. At a median follow-up of 41 months, there were 11 local (16%) and 11 distant (16%) recurrences. The local and distant 5-year recurrence-free survival rates were 72% and 82%, and the 5-year overall survival was 61%. Increased age (scaled by 0.1; hazard ratio [HR] 1.80, P=0.002) and tumor size (HR 1.12, P=0.004) were negatively correlated with overall survival. Positive/close (<1 mm) margin status (HR 4.34, P=0.030) predicted worsened local recurrence-free survival. MFS exhibit a propensity for local recurrence, which is predicted by resection with positive or close margins. Aggressive surgery combined with radiotherapy may contribute to more effective local control.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Radiation Therapy for Treatment of Soft Tissue Sarcoma in Adults: Executive Summary of an ASTRO Clinical Practice Guideline

                Bookmark

                Author and article information

                Contributors
                Journal
                J Radiat Res
                J Radiat Res
                jrr
                Journal of Radiation Research
                Oxford University Press
                0449-3060
                1349-9157
                July 2023
                10 June 2023
                10 June 2023
                : 64
                : 4
                : 746-749
                Affiliations
                Department of Radiation Oncology, Juntendo University School of Medicine , 3-1-3, Bunkyo-ku, Tokyo 113-8431, Japan
                Department of Radiation Oncology, National Cancer Center Hospital , 5-1-1, Chuo-ku, Tokyo 104-0045, Japan
                Department of Musculoskeletal Oncology and Rehabilitation, National Cancer Center Hospital East , 6-5-1, Kashiwa-shi, Chiba 277-8577, Japan
                Department of Radiation Oncology, Juntendo University School of Medicine , 3-1-3, Bunkyo-ku, Tokyo 113-8431, Japan
                Division of Radiation Safety and Quality Assurance, National Cancer Center Hospital , 5-1-1, Chuo-ku, Tokyo 104-0045, Japan
                Department of Radiation Oncology, Juntendo University School of Medicine , 3-1-3, Bunkyo-ku, Tokyo 113-8431, Japan
                Department of Radiation Oncology, National Cancer Center Hospital , 5-1-1, Chuo-ku, Tokyo 104-0045, Japan
                Author notes
                Corresponding author. Department of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan. Email: n.murakami.zi@ 123456juntendo.ac.jp
                Article
                rrad041
                10.1093/jrr/rrad041
                10354856
                37301983
                ccaec2e6-863a-412e-a8bf-b59feea61517
                © The Author(s) 2023. Published by Oxford University Press on behalf of The Japanese Radiation Research Society and Japanese Society for Radiation Oncology.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 21 March 2023
                : 17 April 2023
                : 29 April 2023
                Page count
                Pages: 4
                Categories
                Technical report
                Oncology/Medicine
                AcademicSubjects/MED00870
                AcademicSubjects/SCI00960

                Oncology & Radiotherapy
                Oncology & Radiotherapy

                Comments

                Comment on this article